StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson Cardiovascular Franchise by Quarter

Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson Cardiovascular Franchise: 4.3% in Q3 2026, down 8.3 pts from a year earlier.

Latest, Q3 2026
4.3%
Period ended Sep 30, 2026
Change on a year earlier
-8.3 pts
12.6% in Q3 2025
History
36 quarters
Since Q4 2017
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

“|| WW | 2,307 | 2,213 | 4.3 | 4.1 | 0.2”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCardiovascular (formerly Interventional Solutions) Franchise — Worldwide reported growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 20264.3%-8.3 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 20264.0%-19.5 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 202613.0%-3.4 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202511.5%-12.1 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 202512.6%-13.6 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 202523.5%+7.9 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 202516.4%-3.8 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 202423.6%-28.3 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 202426.2%-20.8 ptsForm 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 202415.6%-38.8 ptsForm 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 202420.2%-17.4 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2023Dec 31, 202351.9%+44.1 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
Q3 2023Oct 1, 202347.0%+36.2 ptsForm 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗
Q2 2023Jul 2, 202354.4%+54.1 ptsForm 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗
Q1 2023Apr 2, 202337.6%+22.5 ptsForm 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 20237.8%-6.3 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗

Cite this data

StockData. (2026). Johnson & Johnson Cardiovascular Franchise (%), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt-cardiovascular-rep-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.